Marcos Schechter
banner
limbsandlungs.bsky.social
Marcos Schechter
@limbsandlungs.bsky.social
Emory Infectious Diseases physician based at Grady Memorial Hospital - ATL, GA. Diabetic foot, tuberculosis, and cycling.
Reposted by Marcos Schechter
New research:

Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study

www.thelancet.com/journals/lan...
Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study
Current treatment options for bedaquiline-resistant tuberculosis result in prolonged therapy, delayed microbiological responses, and poor clinical outcomes. Implementation of more rapid resistance tes...
www.thelancet.com
June 19, 2025 at 1:29 PM
Reposted by Marcos Schechter
Structured linezolid dose reduction (600mg/d➡️300mg/d after 9-13 weeks) had comparable recurrence free cure rates as fixed linezolid 600mg/d when given along with bedaquiline and pretomanid for 26 weeks in PreXDR TB

doi.org/10.1016/j.ji...

#IDSky
June 19, 2025 at 3:46 PM
Reposted by Marcos Schechter
Check out this new ortho ID publication from Dr. Angela Hewlett and many international collaborators in @cmicomms.bsky.social!

"To heal or harm: a systematic review of the role of fluoroquinolones in periprosthetic joint infections"

#IDSky #OrthoID

www.cmi-comms.com/article/S295...
To heal or harm: a systematic review of the role of fluoroquinolones in periprosthetic joint infections
Fluoroquinolones (FQs) are currently recommended for the treatment of periprosthetic joint infections (PJIs) caused by staphylococci and Gram-negative bacteria (GNB) in patients undergoing debridement...
www.cmi-comms.com
June 20, 2025 at 3:11 PM